Failure to respond at 1‐4 weeks · depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · depression
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with escitalopram (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · depression
Paroxetine showed no clear difference in failure to remit at endpoint compared with escitalopram (low certainty).
1 finding from 1 review
SMD at endpoint · depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with escitalopram (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with escitalopram (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with fluoxetine (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine probably leads to lower failure to complete ‐ any cause ‐ compared with older ADs (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ total drop out rate compared with fluoxetine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with fluoxetine (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with fluvoxamine (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
Paroxetine showed no clear difference in failure to respond at 1‐4 weeks compared with fluvoxamine (moderate certainty).
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
Paroxetine showed no clear difference in failure to remit at endpoint compared with fluvoxamine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with fluvoxamine (moderate certainty).
1 finding from 1 review